

Review

Current Knowledge on Mammalian Phospholipase A₁, Brief History, Structures, Biochemical and Pathophysiological Roles

Shun Yaginuma, Hiroki Kawana and Junken Aoki *

Faculty of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan; shunyaginuma-s218@g.ecc.u-tokyo.ac.jp (S.Y.); hiroki-kawana@mol.f.u-tokyo.ac.jp (H.K.)

* Correspondence: jaoki@mol.f.u-tokyo.ac.jp; Tel.: +81-3-5841-4720

Abstract: Phospholipase A₁ (PLA₁) is an enzyme that cleaves an ester bond at the *sn*-1 position of glycerophospholipids, producing a free fatty acid and a lysophospholipid. PLA₁ activities have been detected both extracellularly and intracellularly, which are well conserved in higher eukaryotes, including fish and mammals. All extracellular PLA₁s belong to the lipase family. In addition to PLA₁ activity, most mammalian extracellular PLA₁s exhibit lipase activity to hydrolyze triacylglycerol, cleaving the fatty acid and contributing to its absorption into the intestinal tract and tissues. Some extracellular PLA₁s exhibit PLA₁ activities specific to phosphatidic acid (PA) or phosphatidylserine (PS) and serve to produce lysophospholipid mediators such as lysophosphatidic acid (LPA) and lysophosphatidylserine (LysoPS). A high level of PLA₁ activity has been detected in the cytosol fractions, where PA-PLA₁/DDHD1/iPLA₁ was responsible for the activity. Many homologs of PA-PLA₁ and PLA₂ have been shown to exhibit PLA₁ activity. Although much has been learned about the pathophysiological roles of PLA₁ molecules through studies of knockout mice and human genetic diseases, many questions regarding their biochemical properties, including their genuine *in vivo* substrate, remain elusive.

Citation: Yaginuma, S.; Kawana, H.; Aoki, J. Current Knowledge on Mammalian Phospholipase A₁, Brief History, Structures, Biochemical and Pathophysiological Roles.

Molecules **2022**, *27*, 2487.

<https://doi.org/10.3390/molecules27082487>

Academic Editors: George Kokotos and Jesús Balsinde

Received: 4 November 2021

Accepted: 29 March 2022

Published: 12 April 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Keywords: phospholipase A₁; phospholipid metabolism; lysophospholipid; fatty acid

1. Introduction

Phospholipase A₁ (PLA₁) is an enzyme that hydrolyzes an ester bond at the *sn*-1 position of glycerophospholipids (GPLs), usually producing a saturated or mono-unsaturated fatty acid and a 1-lyso-2-acyl-phospholipid (2-acyl-lysophospholipid, 2-acyl-LPL) (Figure 1). PLA₁ has not attracted as much attention as other mammalian acyl hydrolases, such as phospholipase A₂ (PLA₂), which hydrolyzes fatty acids, mainly unsaturated fatty acids, and acts as a first step in producing enzymes for bioactive lipids such as eicosanoids and platelet-activating factor (PAF) [1,2]. Some PLA₁s and PLA₂ target neutral lipids such as triacylglycerol (TAG) and diacylglycerol (DAG) in addition to GPLs (Figure 1).



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).




Figure 1. Structures of glycerolipids and their metabolic enzymes. **(A)** Glycerophospholipids (GPL) and phospholipases. GPLs are composed of a polar head group (six major classes), a glycerol backbone and fatty acid moieties (esterified at the *sn*-1 and *sn*-2 positions). Phospholipase A₁ (PLA₁) hydrolyzes a fatty acid at the *sn*-1 position, generating *sn*-2-acyl-1-lyso-phospholipids (*sn*-2-acyl LPLs), while phospholipase A₂ (PLA₂) hydrolyzes a fatty acid at the *sn*-2 position generating *sn*-1-acyl-2-lyso-phospholipids (*sn*-1-acyl LPLs). Phospholipase B (PLB) hydrolyzes a fatty acid at both *sn*-1 and *sn*-2 positions. LysoPLA hydrolyzes a fatty acid of *sn*-2-acyl LPLs and *sn*-1-acyl LPLs, generating glycerophosphate compounds. **(B)** Triacylglycerol (TAG) has three fatty acids at the *sn*-1, *sn*-2 and *sn*-3 positions of glycerol backbone, diacylglycerol (DAG) has two fatty acids and monoacylglycerol (MAG) has one fatty acid. TAG lipase hydrolyzes a fatty acid of TAG, generating *sn*-1, 2, *sn*-2, 3 or *sn*-1, 3-diacylglycerols (DAGs). DAG lipase hydrolyzes a fatty acid of DAG and MAG lipase hydrolyzes a fatty acid of MAG.

Much is known about the functions of PLA₂, whereas those of PLA₁ remain limited. However, because fatty acids at both the *sn*-1 and *sn*-2 positions of GPLs have a high turnover rate [3], PLA₁ as well as PLA₂, appears to be involved in the rapid turnover and remodeling of cellular GPLs (Figure 2). In addition, some PLA₁s also have a specific role in the production of 2-acyl-1-lysophospholipids, which serve as lysophospholipid mediators. For example, one type of PLA₁, membrane-associated phosphatidic acid-selective PLA₁ (mPA-PLA₁α in Table 1, Figure 3A), produces 2-acyl-1-lysophosphatidic acid (2-acyl-lysoPA (LPA)) with an unsaturated fatty acid residue [4]. The 2-acyl-LPA acts as a potent ligand for LPAR3/EDG7 and LPAR6/P2Y5, with LPA receptors preferring 2-acyl-LPA over 1-acyl-LPA [5,6]. Phosphatidylserine-specific PLA₁ (PS-PLA₁ in Table 1, Figure 3A) also acts as a producing enzyme of another lysophospholipid mediator, 2-acyl-lyso-phosphatidylserine (2-acyl-lysoPS (LysoPS)), which further supports the idea that PLA₁s function as producing enzymes for lysophospholipid mediators.




Figure 2. Fatty acid remodeling reactions of GPLs. Glycerophospholipids (GPL) in the cells are constantly subjected to two kinds of fatty acid hydrolyzing reactions mediated by phospholipase A₁ (PLA₁) and phospholipase A₂ (PLA₂), resulting in the production of 2-acyl-1-lysophospholipid (*sn-2* LPL) and 1-acyl-2-lysophospholipid (*sn-1* LPL). The LPLs thus produced are further subjected to acylation reactions to re-form the GPLs. Several kinds of lysophospholipid acyltransferases (LPLAT) are responsible for the introduction of fatty acids to lysophospholipids. By these sequential GPL remodeling reactions, the fatty acids of GPLs are constantly replaced.




Figure 3. Physiological roles of extracellular PLA₁s. (A) PS-PLA₁ and mPA-PLA₁α serve as producing enzymes for lysophospholipid mediators. PS-PLA₁ has a strict substrate specificity in that it only acts on serine containing GPLs such as phosphatidylserine (PS) and lysophosphatidylserine (LysoPS). LysoPS then acts on GPCR-type LysoPS receptors. Three such LysoPS receptors have been identified. These include LPSR1/GPR34, LPSR2/P2Y10, and LPSR3/GPR174. mPA-PLA₁α acts on PA in a specific manner and produces *sn-2* LPA, which then acts on GPCR-type LPA receptors, LPAR1-LPAR6 evoking various biological responses. (B) Pancreatic lipase (PL) is secreted from the pancreas into the lumen of the intestine, where it, with the aid of bile acids, hydrolyzes the fatty acids of triacylglycerol (TAG) and GPLs in the digestive juice yielding diacylglycerol (DAG), monoacylglycerol (MAG) and fatty acids. The liberated fatty acids are absorbed by intestinal cells as nutrients. (C) Lipoprotein lipase (LPL), hepatic lipase (HL), and endothelial lipase (EL), which are mainly present in the blood, are associated with endothelial cell surfaces in adipose tissues (LPL), heart (LPL), liver (HL) and various tissues. These lipases have both TAG lipase and PLA₁ activities. They hydrolyze fatty acids of TAG and GPLs present in the circulating lipoproteins such as low-density lipoproteins (LDL) and high-density lipoproteins (HDL), yielding diacylglycerol (DAG), monoacylglycerol (MAG), lysophospholipids (LPL) and fatty acids. The free fatty acids are absorbed by corresponding cells for energy source and storage of neutral lipids.

Although PLA₁ activity has been detected in many mammalian tissues and cells [7–14], only a few PLA₁s have been purified and cloned. Some triacylglycerol (TAG)-hydrolyzing lipases (Figure 1) such as hepatic lipase, endothelial cell lipase, and lipoprotein lipase also show PLA₁ activity [15].

Table 1. Mammalian PLA₁s.

	Primary name	Other name	Human gene	Substrate	Reaction mediated	PDB ID (H: Human, R: Rat)	Ref.
	PS-PLA ₁	PLA1A	<i>PLA1A</i>	PS	Producing enzyme for bio-active lysophospholipid, LysoPS	-	[16,17]
	PA-PLA ₁ α	LIPH, mPA-PLA ₁ α	<i>LIPH</i>	PA	Producing enzyme for bio-active lysophospholipid, LPA	-	[4,18]
extracellular PLA ₁ s	lipoprotein lipase	LPL, LIPD	<i>LIPD</i>	TAG, PL	TAG lipase and PLA ₁ activity	H: 6E7K, 6OAU, 6OAZ, 6OB0, 6WN4	[19]
	hepatic lipase	HL, LIPC	<i>LIPC</i>	TAG, PL	TAG lipase and PLA ₁ activity	-	[19]
	endothelial cell-derived lipase	EDL, EL, LIPG	<i>LIPG</i>	PL	Predominant PLA ₁ activity	-	
	pancreatic lipase	PL, PNLIP	<i>PNLIP</i>	TAG, PL	TAG lipase and PLA ₁ activity	H: 1GPL, 1LPA, 1LPB, 1N8S	[15,20,21]
	pancreatic lipase-related protein 1	PLRP1	<i>PLRP1</i>	TAG, PL	TAG lipase and PLA ₁ activity	H: 2PPL	
	pancreatic lipase-related protein 2	PLRP2	<i>PLRP2</i>	TAG, PL	TAG lipase and PLA ₁ activity	H: 2OXE, 2PVS; R: 1BU8	[15,21]
		PA-PLA ₁ KIAA0725p	DDHD1, iPLA ₁ α DDHD2, iPLA ₁ γ	<i>DDHD1</i> <i>DDHD2</i>	PL PL	PLA ₁ activity PE, DAG, CL	- -
	p125	iPLA ₁ β	<i>P125</i>	n.d.	Enzymatic activity has not been detected	-	[27]
intracellular PLA ₁ s	PNPLA6	iPLA ₂ δ, NTE	<i>PNPLA6</i>	PC, LPC	PLB, LysoPLA activity cleaving FAs at both <i>sn</i> -1 and <i>sn</i> -2 positions	-	[28–30]
	PNPLA7	iPLA ₂ θ, NRE	<i>PNPLA7</i>	PC, LPC	PLB, LysoPLA activity cleaving FAs at both <i>sn</i> -1 and <i>sn</i> -2 positions	-	[31]
	PNPLA8	iPLA ₂ γ, Group VIB PLA ₂	<i>PNPLA8</i>	PC	PLB activity cleaving FAs at both <i>sn</i> -1 and <i>sn</i> -2 positions	-	[32,33]
	cPLA ₂ α	PLA2G4A, Group IVA PLA ₂	<i>PLA2G4A</i>	PL	PLB activity cleaving FAs at both <i>sn</i> -1 and <i>sn</i> -2 positions	H: 1BCI, 1CJY, 1RLW	[34]
	cPLA ₂ β	PLA2G4B, Group IVB PLA ₂	<i>PLA2G4B</i>	PL	PLB activity cleaving FAs at both <i>sn</i> -1 and <i>sn</i> -2 positions	-	[35,34]
	cPLA ₂ ζ	PLA2G4F, Group IVF PLA ₂	<i>PLA2G4F</i>	PL	PLB activity cleaving FAs at both <i>sn</i> -1 and <i>sn</i> -2 positions	-	
	PLA2G16	Group XVI PLA ₂ , PLAAT3, HRASLS3, H-Rev107	<i>PLA2G16</i>	PL	PLB activity cleaving FAs at both <i>sn</i> -1 and <i>sn</i> -2 positions	H: 2KYT, 4DOT, 4FA0, 4Q95, 7C3Z, 7C41	[36]

2. History of PLA₁ Research

The following is a brief history of mammalian PLA₁ research. PLA₁ as well as PLA₂ activities have been detected in various tissues and plasma. In the 1990's, two PLA₁ molecules were biochemically purified and identified. These two PLA₁s are phosphatidic acid-preferential PLA₁ (PA-PLA₁) and phosphatidylserine-specific PLA₁ (PS-PLA₁) (Table 1). In 1994, Higgs and Glomset purified a novel PLA₁ from a cytosolic fraction of bovine testes that preferentially hydrolyzed PA [22] (Table 1). Shortly after, the same group cloned a cDNA of the PLA₁, and PA-PLA₁ was found to be an intracellular protein composed of 875-amino acids with a calculated molecular mass of approximately 100 kDa. Simultaneously, Exton's group purified a very similar PLA₁ from the bovine brain [37]. It was not clear whether the two intracellular PLA₁s were identical, because the two groups used different PLA₁ assay conditions and substrates. Later, Kudo's group purified similar PLA₁s from the brain and testes of mice, rats, and cows [38] and showed that they were identical to the PA-PLA₁ mentioned above. They demonstrated that PA-PLA₁ was predominantly hydrolyzed phosphatidic acid (PA) in the presence of Triton X-100 and phosphatidylethanolamine (PE) in its absence. The result showed clearly that the substrate specificity of PA-PLA₁ in vitro is affected by the assay conditions, which makes it difficult to identify the natural substrates of PA-PLA₁. This also implies that the name, PA-PLA₁, is not suitable for the enzyme.

Horigome et al. detected two PLA activities in the supernatant of activated rat platelets [39,40]. One was identified as secretory PLA₂, now known as Group IIA secretory phospholipase A₂ (sPLA₂IIA). Sato et al. succeeded in purifying and cloning another PLA that showed a high preference for serine-containing phospholipids [16]. The PLA is now known as PS-specific PLA₁ (PS-PLA₁) (Table 1). PS-PLA₁ specifically hydrolyzed PS in vitro. In addition, it acted on the intact cell membrane, hydrolyzed PS and produced 2-acyl-LysoPS. Thus, PS-PLA₁ is believed to be a LysoPS-producing enzyme.

The 3D structures of three PLA₁ family members (extracellular PLA₁/lipase, cPLA₂ and PLAAT family members) were shown. For extracellular PLA₁/lipase family members, β 5 and the β 9 loops and the lid domain are shown in yellow, cyan and green, respectively. The three residues forming a catalytic triad (Ser, Asp and His) are described as sticks (red). For cPLA₂ family members (cPLA₂ α , cPLA₂ β and cPLA₂ ζ), the conserved lipase motifs (GXSGX and DXG) are shown in red, and the two residues forming a catalytic dyad (Ser and Asp) are shown as sticks. For PLAAT3/PLA2G16, the three residues forming a catalytic triad (two histidines and cysteine) are shown as sticks (red). The structures without asterisk were acquired from RCSB Protein Data Bank. (Reference PDB IDs; PL (1LPB), LPL (6OB0), PLRP1 (2PPL), cPLA₂ α (1CJY), PLA2G16 (4DOT)). The predicted structures of lipases denoted with an asterisk were acquired from AlphaFold Protein Structure Database. All the structures were visualized using PyMOL software.

After discovering the two PLA₁ molecules, several researchers found similar PLA₁s (homologs) in the nucleotide databases, expressed them as recombinant proteins and characterized them biochemically. These analyses identified the homologs as novel PLA₁s. These include extracellular enzyme membrane-associated PA-selective PLA₁ α (mPA-PLA₁ α , a PS-PLA₁ homologue) [4] (Table 1) and intracellular enzyme iPLA₁ γ /DDHD2/KIAA0725 (a PA-PLA₁ homologue) [24] and iPLA₁ β /SEC23IP/p125 (PLA₁ activities have not been detected) [27] (Table 1). In addition, similar biochemical characterization was performed for PLA₂ homologs. Interestingly, biochemical characterizations of the PLA₂ homologs showed that some of them exhibited PLA₁ activity in addition to their PLA₂ activity (PLB activity (Figure 1)) (Table 1). It should also be noted here that certain lipases that hydrolyze TAG have PLA₁ activity, as mentioned above (Table 1). Lipases hydrolyze fatty acids at the *sn*-1 and *sn*-3 positions of triacylglycerol (TAG) and diacylglycerol (DAG). They also hydrolyze fatty acids at the *sn*-1 or *sn*-3 positions of monoacylglycerol (MAG). This review will summarize current knowledge on PLA₁ molecules reported thus far, discussing their discoveries, structures, tissue and cellular distributions, and possible biological functions.

PLA₁s are roughly divided into two groups: (1) extracellular PLA₁/lipase family and (2) intracellular PLA₁ family (Table 1), depending on their cellular localization and primary amino acid sequences. The intracellular PLA₁ family was further subdivided into several groups, consisting of an iPLA₁ family, PNPLA family, cPLA₂ family and PLAAT family.

In the following sections, we will summarize what has been known to date about each family member regarding the history of discovery, biochemical characterization, expression, structural feature and function at animal and cellular levels.

3. Structural Evaluation of PLA₁ Molecules

Recently, a computational machine learning method named AlphaFold was developed enabling researchers to predict protein structures with high accuracy, even when no similar experimentally solved structure is available [41]. In this review, we utilized AlphaFold to generate structural predictions of PLA₁ molecules. Figure 4 summarizes the AlphaFold-generated structures of some PLA₁ molecules focused on in this review. Note that some structures have been determined, e.g., by X-ray crystallography, while others were structure-predicted. Since structures of any PNPLA and iPLA₁ family members have not been determined, AlphaFold was unable to predict their structures. Thus, predicted structures were shown only for extracellular PLA₁/lipase and for cPLA₂ family members (Figure 4).




Figure 4. Structures of PLA₁ molecules. 3D structures of three PLA₁ family members (extracellular PLA₁/lipase, cPLA₂ and PLAAT family members) were shown. For extracellular PLA₁/lipase family members, β 5 and the β 9 loops and the lid domain are shown in yellow, cyan and green, respectively. The three residues forming a catalytic triad (Ser, Asp and His) are described as sticks (red). For cPLA₂ family members (cPLA₂ α , cPLA₂ β and cPLA₂ ζ), the conserved lipase motifs (GXSGX and DXG) are shown in red, and the two residues forming a catalytic dyad (Ser and Asp) are shown as sticks. For PLAAT3/PLA2G16, the three residues forming a catalytic triad (two histidines and cysteine) are shown as sticks (red). The structures without asterisk were acquired from RCSB Protein Data Bank. (Reference PDB IDs; PL (1LPB), LPL (6OB0), PLRP1 (2PPL), cPLA₂ α (1CJY), PLA2G16 (4DOT)). The predicted structures of lipases with asterisk were acquired from AlphaFold Protein Structure Database. All the structures were visualized using PyMOL software.

4. Extracellular PLA₁/Lipase Family Members

4.1. Phosphatidylserine-Specific Phospholipase A₁ (PS-PLA₁)

4.1.1. Historical Aspects

PS-PLA₁ was originally found as a lysophosphatidylserine-selective lysophospholipase (LysoPS-lysophospholipase) that was detected in the cell supernatant of activated rat platelets together with Group IIA secretory phospholipase A₂ (sPLA₂ IIA) [40,42]. The purified LysoPS-lysophospholipase was later found also to exhibit PS-PLA₁ activity [16].

4.1.2. Biochemical Characterization and Tissue Distribution

Activated rat platelets secreted PS-PLA₁ and sPLA₂-IIA, both of which are stored in α -granules [40]. Sato et al. purified PS-PLA₁ from a culture medium of thrombin-activated platelets prepared from approximately 1000 rats [16]. In rats, PS-PLA₁ is expressed in platelets and in the heart and lung [17,43]. The expression of PS-PLA₁ in platelets was species-dependent. For example, PS-PLA₁ mRNA was poorly expressed in human platelets but highly expressed in rat platelets.

Interestingly, enhanced PS-PLA₁ expression was detected in many tissues when rats were treated with bacterial lipopolysaccharide in vivo (our unpublished observation). Recently, Yatomi et al. established a PS-PLA₁ immunoassay [44] and subsequently reported that PS-PLA₁ antigen concentrations were variable in clinical samples from patients. Serum PS-PLA₁ was significantly elevated in patients with autoimmune disorders, including systemic lupus erythematosus (SLE), rheumatoid arthritis, and Sjogren's syndrome [45]. Interestingly, the level of PS-PLA₁ in each SLE individual showed an excellent association with the SLE disease activity index and decreased after the commencement of medical therapy.

PS-PLA₁ reacts specifically with PS and 1-acyl-LysoPS [39,46]. It cannot appreciably hydrolyze any other phospholipids, including phosphatidyl-D-serine. The enzyme is not a type of PLB because it exclusively hydrolyzes an acyl residue bound at the *sn*-1 position of either PS or 1-acyl-LysoPS. Incubation of the enzyme with 1-acyl-2-radioactive acyl-PS produced radioactive LysoPS but only a tiny amount of radioactive-free fatty acid, even after long-term incubation [16]. It can be concluded that PS-PLA₁ recognizes a 1-acyl-glycerophospho-L-serine structure and hydrolyzes an acyl residue at the *sn*-1 position. PS-PLA₁ may first interact with the bilayer structure's surface to gain access to PS molecules buried in the bilayer.

4.1.3. Structural Characteristics

PS-PLA₁ belongs to the lipase family, which is composed of classical lipases such as lipoprotein lipase (LPL), hepatic lipase (HL), endothelial lipase (EL), membrane-associated phosphatidic acid-selective PLA₁ α (mPA-PLA₁ α) and mPA-PLA₁ β (Table 1). They share approximately 30–50% amino acid identity. The sequence homology of PS-PLA₁ was about 80.0% between humans [17] and rats [16]. The deduced amino acid sequence contains a catalytic triad composed of active Ser, Asp, His residues, and "lid" surface loops (Figure 4). Interestingly, conventional lipases have long "lid" (22–23 residues) and " β 9" loops (18–19 residues), whereas PS-PLA₁ has a shorter "lid" (12 residues) and a shorter (deleted) " β 9" loop (13 residues) [16,17]. Both loops, which may be strengthened by disulfide bonds linking 14 cysteine residues, have been implicated in substrate recognition. These findings are compatible with the fact that PS-PLA₁ activity was sensitive to diisopropylfluorophosphate and dithiothreitol [42].

4.1.4. Possible Functions

LysoPS has been shown to stimulate histamine release from rat peritoneal mast cells triggered by cross-linking of Fc ϵ RI, a high-affinity receptor for IgE [47–50]. Interestingly, recombinant PS-PLA₁ protein had activity similar to that of LysoPS [51], indicating that PS-PLA₁ interacts with PS in the mast cell plasma membrane to produce LysoPS. Because the PS-PLA₁-induced degranulation was significantly enhanced in the presence of apoptotic cells [51], cells that surround the mast cells, such as neutrophils in the peritoneal cavity rather than mast cells, must be the source of PS. For example, a crude preparation of rat peritoneal mast cells (containing other cell types such as mononuclear leukocytes and neutrophils) released appreciable amounts of histamine in the presence of PS-PLA₁ and an Fc receptor cross-linker [51].

PS-PLA₁ also serves as a LysoPS-producing enzyme for cloned LysoPS receptors (Figure 3A). In a TGF α -shedding assay in which an ectodomain shedding of TGF α detects GPCR activation, PS-PLA₁ and LysoPS can induce the TGF α shedding in LPSR1/GPR34 (a LysoPS receptor). Thus, it is likely that PS-PLA₁ acts as a LysoPS-producing enzyme for LPSR1/GPR34. This hypothesis is further supported by the fact that PA-PLA₁ α /LIPH (see below) is a close homolog of PS-PLA₁ and serves to produce LPA to activate an LPA receptor, LPAR6.

4.2. Membrane-Associated Phosphatidic Acid-Selective Phospholipase A₁s (mPA-PLA₁ α /LIPH and mPA-PLA₁ β)

4.2.1. Historical Aspects

Lysophosphatidic acid (LPA or lysoPA) is a lipid mediator with multiple biological functions. These include physiological functions such as brain development (LPAR1), embryo implantation (LPAR3), blood vessel formation (LPAR4 and LPAR6), and hair follicle development (LPAR6), and has also been implicated in pathological conditions such as the development of fibrosis (LPAR1), endometriosis (LPAR3) and obesity (LPAR4). LPA induces platelet aggregation, smooth muscle contraction, stimulation of cell proliferation, formation of actin stress fibers in fibroblasts, and inhibition of neurite outgrowth in neuronal cells at the cellular level. Recent studies have identified a new family of receptor genes for LPA. A total of three G-protein-coupled receptors (GPCR) belonging to the EDG (endothelial differentiation gene) family (LPAR1/EDG2, LPAR2/EDG4, and LPAR3/EDG7) and another three belonging to the P2Y family (LPAR4/P2Y9, LPAR5/GPR192, LPAR6/P2Y5) have been identified [6,52,53]. LPA with an unsaturated fatty acid at the *sn*-2 position of the glycerol backbone preferentially activates LPAR3 and LPAR6 [5,6]. Interestingly, such LPA with an unsaturated fatty acid may have specific functions. For example, Hayashi et al. found that LPA with an unsaturated fatty acid (unsaturated LPA) but not LPA with a saturated fatty acid stimulated dedifferentiation of rat smooth muscle cells isolated from blood vessels [54]. Tokumura et al. also reported that unsaturated LPA stimulated the proliferation of smooth muscle cells in vitro [55]. Kurano et al. reported that unsaturated LPA such as DHA-LPA and arachidonic acid-containing LPA increased in plasma from acute coronary syndrome (ACS) patients. ACS is the rapid narrowing or occlusion of the coronary artery lumen caused by the collapse of an unstable plaque formed by atherosclerosis and thrombus formation [56].

In the process of the production of unsaturated LPA, PLA₁ must be involved. There have been two pathways postulated [57]. In one pathway, phospholipids are subjected to the PLA₁ reaction to produce lysophospholipids with unsaturated fatty acids. Then, the unsaturated lysophospholipids are converted to unsaturated LPA by phospholipase D (PLD) type enzymes. Little is known about the identity of PLA₁, but the PLD enzyme has been identified as autotaxin (ATX). In the other pathway, phosphatidic acid (PA) is converted to unsaturated LPA by phosphatidic acid-selective phospholipase A₁s. Two such PLA₁s were cloned and characterized, mPA-PLA₁ α [4] and mPA-PLA₁ β [18], both of which are close homologs of PS-PLA₁ (Table 1). PA-PLA₁ α is expressed explicitly in hair

follicles and plays a critical role in forming proper structures of hair follicles by activating LPAR6.

4.2.2. Biochemical Characterization and Distribution

When expressed in insect Sf9 cells, neither mPA-PLA₁α nor mPA-PLA₁β protein was recovered from the culture medium, although both have signal sequences at the N-terminus. Instead, both were recovered from the detergent-resistant membrane domains, referred to as raft structures [18].

Human mPA-PLA₁α is most abundantly expressed in the hair follicle, where, as stated above, it regulates the formation of hair follicles [58]. A closely homologous enzyme, mPA-PLA₁β, was found in the gene bank. The characteristics of mPA-PLA₁β were similar to those of mPA-PLA₁α, except that it was exclusively detected in human testes. Although mPA-PLA₁β was detected in sperm, only a small amount was detected in seminal fluids [18]. Interestingly, a high mPA-PLA₁β expression was frequently observed in some rare testes cancers, including Ewing family tumor, although its role in cancer remains unclear [59].

Both mPA-PLA₁α and mPA-PLA₁β were found to exhibit PLA₁ activity against PA. Other GPL substrates and TAG were not substrates for mPA-PLA₁α and mPA-PLA₁β [4,18].

4.2.3. Structural Characteristics

The deduced amino acid sequence of mPA-PLA₁α shares 34.0% identity with that of human PS-PLA₁ [4], and the N-terminal half of the molecule has about 40% identity with the N-terminal catalytic domain of PS-PLA₁. In total, three of the amino acid residues in the sequences of mPA-PLA₁α, Ser-154, Asp-178, and His-248, are completely conserved among lipases (Figure 4). The deduced amino acid sequences of mPA-PLA₁α and mPA-PLA₁β are 45.9% identical. The homologous regions were again most prominent in the first half of the molecule. The amino acid lengths of three loop structures, β5, β9 and lid, were exactly the same as in PS-PLA₁ and mPA-PLA₁β (Figure 4), while they were quite different in other lipase family members. Thus, these loop structures are believed to be involved in the substrate recognition.

4.2.4. Function

In vitro, both mPA-PLA₁α and mPA-PLA₁β showed PA-specific PLA₁ activity [4,18]. Both enzymes appear to produce LPA at the cellular level. High LPA was detected in cells expressing mPA-PLA₁α, especially when the cells were treated with bacterial phospholipase D to produce PA on the cell surface [4]. Of note, no appreciable change was observed in the level of any other lysophospholipids under the same conditions [4], indicating that mPA-PLA₁α has high substrate specificity for PA. In 2006, Kazantseva reported that a gene encoding mPA-PLA₁α (also called Lipase H or LIPH) is a causative gene for an inherited form of hair loss and hair growth defect [60]. After the discovery, similar defects in the mPA-PLA₁α/LIPH gene were identified all over the world. In addition, a gene whose mutation causes unusual hairiness in dogs and rabbits was reported to encode mPA-PLA₁α/LIPH. Moreover, we showed that mPA-PLA₁α/LIPH knockout mice displayed similar woolly or wavy hair [58]. Thus, it is now generally accepted that mPA-PLA₁α/LIPH plays a critical role in hair growth in a wide range of mammals.

In 2008, Shimomura et al. and Pasternack et al. performed a genetic linkage analysis in several families with autosomal recessive woolly hair and showed linkage to chromosome 13q14.2–14.3 in which an orphan G protein-coupled receptor P2Y5 was mapped [61,62]. Later Yanagida et al. and Inoue et al. showed that P2Y5 was a receptor for LPA, now called LPAR6. Of note, LPAR6 prefers LPA with an unsaturated fatty acid at the *sn*-

2 position. Thus, it is reasonable to assume that mPA-PLA₁α/LIPH is an enzyme that supplies LPA to GPCR-type LPA receptors, also called LPAR6/P2Y5 receptors [63] (Figure 3A).

4.3. Extracellular Lipases

In addition to above-described PS- and PA-specific PLA₁s, specific extracellular lipases exhibit PLA₁ activity in addition to their intrinsic lipase activity to hydrolyze triacylglycerol (TAG) (Figure 1). These include pancreatic lipase (PL), lipoprotein lipase (LPL), hepatic lipase (HL), endothelial lipase (EL), and pancreatic lipase-related protein 2 (PLRP2) (Table 1), all of which belong to the pancreatic lipase family together with the PS-PLA₁, mPA-PLA₁α and mPA-PLA₁β as mentioned earlier.

4.3.1. Historical Aspects

Lipases hydrolyze TAG present in food or the blood. PL and PLRP2 are secreted from the pancreas and hydrolyze TAG in the small intestine. By contrast, LPL, HL, and EL are mainly present in the blood, where they bind to the surfaces of endothelial cells via heparan sulfate proteoglycans. Both types of lipases catalyze a reaction to hydrolyze ester bonds of TAG at either *sn*-1 or *sn*-3 positions to produce diacylglycerols and fatty acids [15,19]. Interestingly, in addition to their lipase activities, all lipases exhibit considerable PLA₁ and lysophospholipase activities toward PC and LPC. The precise substrate specificities of the lipases have not been demonstrated, but PC is the most probable phospholipid substrate since its levels are much higher than those of other phospholipid species in both blood and foods.

4.3.2. Structural Characteristics

As noted above, all lipases belong to the pancreatic lipase gene family. The family is conserved in a wide range of animals, from insects to mammals [15]. Presently eight members are known in humans (Table 1). Crystallographic studies of human pancreatic lipases [20] revealed that each of the lipases are composed of N- and C-terminal domains. The N-terminal domains are the sites of catalytic activity. Interestingly, all lipase-like molecules observed in insects (*Drosophila melanogaster*, *Bombyx mori*, and hornet) bear only the N-terminal domain [64], supporting the idea that the N-terminal domain is required for catalytic activity. Three amino acid residues in the N-terminal domains, Ser, Asp, and His, form a catalytic triad located in N-terminal domains and are conserved in the pancreatic lipase gene family (Figure 4). In addition, well-conserved cysteine residues that form intramolecular disulfide bonds are present in the N-terminal domains. These structural features indicate that common catalytic machinery is used for both PL and TAG hydrolysis. The crystallographic studies also revealed that human PL contains three surface loops called the lid, the β5 loop, and the β9 loop covering the active sites and have been implicated in the substrate specificity [20,21] (Figure 4). Interestingly, as mentioned above the length of the loop structures are quite different between lipases (PL, LPL, HL and EL) and PLA₁s (PS-PLA₁, mPA-PLA₁α and mPA-PLA₁β), indicating that these loops determine the substrate specificity of lipase family members.

4.3.3. Functional Characteristics

PL and PLRP2 are present in pancreatic juice and contribute to the intestinal absorption of lipids by hydrolyzing various types of glycerolipids, including TAG, diacylglycerol (DAG), monoacylglycerol (MAG), phospholipids, and lysophospholipids (Figure 3B). The resulting free fatty acids, MAG, and lysophospholipids are then absorbed by intestinal epithelial cells and re-build TAG in the form of lipoproteins (chylomicrons) in the cells.

LPL, HL, and EL share a common role in the metabolism of lipoproteins (Figure 3C). LPL is mainly synthesized by adipose tissues and other tissues such as heart muscle, and HL and EL are synthesized by hepatocytes and endothelial cells, respectively. LPL and HL play roles in the tissue uptake of free fatty acids from lipoproteins. LPL is bound to the capillary endothelium and supplies the underlying tissues with fatty acids derived from the TAG-rich chylomicrons and very-low-density lipoprotein (VLDL). EL and HL exhibit PLA₁ activities toward PC on HDL in addition to their TAG-lipase activities. Their PLA₁ activities are partly responsible for their actions in lipoprotein metabolism [65,66]. Interestingly, EL predominantly exhibits PLA₁ activity, whereas HL exhibits both PLA₁ and TAG-hydrolyzing activities. Of note, EL inhibition dramatically increases the level of HDL, which suggests that EL PLA₁ activity has a role in the metabolism of HDL, which is rich in GPLs.

5. Intracellular PLA₁ Families

5.1. *i*PLA₁ Family

5.1.1. Historical Aspects

Most mammalian cells contain cytosolic PLA₁s. Cytosolic PLA₁ activities have been studied in various tissues, including the heart, brain, and testes. Accordingly, a PLA₁ protein, designated phosphatidic acid-preferring phospholipase A₁ (PA-PLA₁, *i*PLA_{1a}) (Table 1), was purified from the brain [37] and testes [22,67]. As with the activities of other lipolytic enzymes, the activities of the PA-PLA₁s were affected considerably by assay conditions. Using a mixed micelle system, Glomset and colleagues [22] found that a 110 kDa enzyme from testes preferentially hydrolyzed PA, which provides the reason for its name PA-PLA₁. They cloned a bovine cDNA for PA-PLA₁ from bovine [23]. PA-PLA₁ was shown to be a unique phospholipase since it lacked sequence similarity to any phospholipases identified thus far, including extracellular PLA₁s, lysophospholipase, LCAT, and triacylglycerol lipases. Since PA-PLA₁ has a DDHD domain, it is also called DDHD1 (Table 1).

Later, two orthologues of PA-PLA₁ were identified in the database (Table 1). One was p125 which was also identified as a protein that interacted with mammalian Sec23p [27]. Sec23p is a component of the COPII coat that functions in the production of membrane traffic vesicles from the ER [68]. The p125 protein is localized in the ER Golgi intermediate compartment (ERGIC) and cis-Golgi, and its overexpression causes the dispersion of these membrane compartments, suggesting that it is involved in the early secretory pathway. Interestingly, p125 did not exhibit appreciable PLA₁ activity. The other is KIAA0725p which is also known as DDHD2. KIAA0725p was shown to have PLA₁ activity for various GPLs, including phosphatidic acid in an assay system containing Triton X-100.

The structures of neither *i*PLA_{1α}/PA-PLA₁/DDHD1, *i*PLA_{1β}/SEC23IP nor *i*PLA_{1γ}/KIAA0725p/DDHD2 have been determined. Therefore, AlphaFold poorly predicted the precise structures of these proteins, except near the active center, where they displayed weak structural similarities with other hydrolases (Figure 4).

5.1.2. Phosphatidic Acid-Preferring Phospholipase A₁ (PA-PLA₁)/ DDHD1/iPLA₁ α Characterization and Distribution

PA-PLA₁ is highly expressed in the testes and brain in a wide range of mammals. It has multiple phosphorylated serine and threonine residues [69,70]. The molecular mass of the expressed PA-PLA₁ was estimated to be about 110 kDa [22]. The PLA₁ activity of PA-PLA₁ was inhibited by methyl arachidonoyl fluorophosphonate (MAFP), an inhibitor of certain PLA₂s, but not by diisopropylfluorophosphate (DFP) [71] a potent inhibitor of PA-PLA₁. The activity of PA-PLA₁ was Ca²⁺-independent at a neutral pH but Ca²⁺-dependent at an alkaline pH [71].

Substrate Specificity

Studies *in vitro* showed that the activity of PA-PLA₁ against PA was 4- to 10-fold greater than the activities of PA-PLA₁ against PI, PS, PE, and PC in a Triton X-100 mixed micelle system [71]. In the absence of Triton X-100, PE was the best substrate for PA-PLA₁ [38]. In addition, the PLA₁ activities were affected by the presence of divalent cations and GPL composition of the substrate [72]. Thus, further studies are needed to identify the real substrates in the cells and *in vivo*. Precise lipidomic analyses will clarify the substrate in the near future.

Function

Spastic paraplegias (SPGs) are neurological disorders characterized by spasticity and gait disturbance. More than 60 types of SPGs caused by mutations in different genes have been reported [73]. SPG type 28 (SPG28) is one type of SPG caused by recessive mutations in the gene encoding PA-PLA₁ α /DDHD1 [74]. How the deficiency of PA-PLA₁ α /DDHD1 leads to the development of the disease has not been identified, but it was shown recently, that the level of lysophosphatidylinositol (LPI) with arachidonic acid (20:4) at the *sn*-2 position decreased in the brains of aged PA-PLA₁ α /DDHD1 knockout mice [75,76], suggesting the potential role of 20:4-LPI in PA-PLA₁ α /DDHD1-mediated signals.

PA-PLA₁ α /DDHD1 is also highly expressed in the testes, where it plays a role in spermatogenesis. Baba et al. reported that PA-PLA₁ α /DDHD1-deficient mice have abnormally shaped sperm, possibly due to the dysregulation of mitochondria of the cells [77]. They speculated that PA metabolism is involved in mitochondrial regulation since PA has been implicated in the fusion and fission cycles of mitochondria. However, one should be cautious about identifying the substrates of PA-PLA₁/DDHD1, because PA may not be an endogenous substrate for PA-PLA₁/DDHD1 as discussed above.

5.1.3. KIAA0725p/DDHD2, a Second Member of Intracellular PLA₁

Historical Aspects

A search of the databases revealed a protein encoded by the human expressed sequence tag clone KIAA0725p that exhibited strong sequence similarity (52.6%) to p125 throughout the entire sequence determined [24]. KIAA0725p has 711 amino acids with a calculated molecular mass of about 80 kDa, and similar to p125, it has a Gly-X-Ser-X-Gly consensus sequence. KIAA0725p also contains a DDHD domain and thus has also been called DDHD2 (Table 1).

Characterization and Distribution

KIAA0725p is a cytosolic protein. Both Northern and Western blot analyses showed a ubiquitous distribution of KIAA0725p [24]. However, unlike PA-PLA₁/DDHD1 most of the KIAA0725p/DDHD2 protein was recovered in the membrane fraction. Immunostaining of the protein indicated KIAA0725p/DDHD2 was associated with membrane structures. The post-nuclear supernatant of cells transfected with KIAA0725p cDNA showed high hydrolytic activities against PE and PA and low activities against PS and PC in the absence of Triton X-100. In the presence of Triton X-100, however, it had activity against PA, but only weak activity against PE [24]. KIAA0725p/DDHD2 also exhibits TAG and DAG lipase activities [25,26].

Function

Overexpression of KIAA0725p was found to cause a morphological change of organelles, such as dispersion of the ERGIC and Golgi apparatus [24]. Morikawa et al. showed that KIAA0725p is one of the factors mediating a membrane transport pathway between the ER and the Golgi that is distinct from the previously characterized COPI- and Rab6-dependent pathways [78]. KIAA0725p/DDHD2 mutations cause autosomal recessive hereditary spastic paraplegia (SPG54) and abnormal mitochondrial morphology [79]. KIAA0725p/DDHD2 KO mice also show defects in locomotion and cognition, and KO MEF exhibits mitochondrial dysfunction [26,80]. Little is known about the lipids responsible for these abnormalities. Further studies are needed to identify the function of the protein.

5.2. Other Recently Identified Intracellular PLA₁s

After the human genome project was completed, many putative PLA molecules were identified in the databases that showed significant homology to previously identified and characterized PLA₁/PLA₂ molecules. Of note, some molecules were indeed shown to display PLA₁, lysophospholipase, and phospholipase B activities. An example is PLB, which hydrolyzes a fatty acid at both *sn*-1 and *sn*-2 positions. Here, we summarize the molecular features of these enzymes.

5.2.1. iPLA₂/PNPLA Family

The iPLA₂ (Ca²⁺-independent phospholipase A₂) family members adopt a three-layer $\alpha/\beta/\alpha$ architecture and harbor an enzymatically active site composed of a Ser-Asp catalytic dyad. They are also called PNPLA (patatin-like phospholipase domain-containing) family members [81] because they do not require Ca²⁺ ions for their activity and have a domain structure similar to that of plant lipase patatin family members. Some of these enzymes exhibit not only PLA₂ activity but also PLA₁ and lysophospholipase activity (PLB (phospholipase B) activity). Among the eight members of the iPLA₂ family, at least three of them (PNPLA6/iPLA₂ δ /NTE, PNPLA7/iPLA₂ θ /NRE, and PNPLA8/iPLA₂ γ /group VIB PLA₂) (Table 1) appear to have PLA₁ activity.

PNPLA6/iPLA₂δ/NTE

- Historical Aspects

PNPLA6 is also known as NTE (neural target esterase) since it was identified as a target molecule for organophosphorus insecticides, which cause neurological disorders such as paralysis of the lower limbs due to degeneration of axons in the spinal cord and peripheral nerves [82]. Later the endogenous substrates for this enzyme were suggested to be GPLs, as shown in the following sections.

- Biochemical Characterization and Tissue Distribution

PNPLA6 shows lysophospholipase activity toward lysophospholipids (especially LPC), producing fatty acids and glycerophosphocholine (GPC) [28]. The enzyme is also conserved in yeast and fruit flies, and these orthologues show phospholipase B activity, hydrolyzing fatty acids both at the *sn*-1 and *sn*-2 positions of PC to produce LPC and GPC [29,30]. PNPLA6 is highly expressed in the nervous system.

- Structural Characteristics

PNPLA6 contains an extended N-terminal domain and three nucleotide-binding motifs in contrast to the common Patatin domain of the iPLA₂ family. PNPLA6 has a transmembrane region near the N-terminus, which was not found in other family members except for PLPLA7.

- Possible Functions

Systemic homozygous deficiency of PNPLA6 in mice has been reported to result in fetal lethality due to placental dysfunction. Heterozygous mice show an increased spontaneous locomotor activity and hyperactivity tendencies [82,83]. Progressive neurodegenerative abnormalities were observed in the hippocampus, thalamus, and cerebellum in mice with neuron-specific deficiency [84]. Mutations near the active center of PNPLA6 in humans have been reported to be responsible for hereditary diseases such as spasticity, ataxia, hypogonadism, and retinal degeneration (Boucher–Neuhäuser syndrome, Laurence–Moon syndrome, Oliver–McFarlane syndrome, and spastic paraplegia) [85–87]. The molecular mechanism underlying the PNPLA6-deficiency-induced neurodegeneration remains obscure. However, it has been proposed that glycerophosphocholine (GPC), the final product of PLB reaction from PC, produced in the kidney, may function as an osmotic regulator since its expression is induced by high NaCl concentrations [88].

PNPLA7/iPLA₂θ/NRE

- Historical Aspects

PNPLA7 is a close relative of PNPLA6/NTE and is therefore named NRE (NTE-related esterase).

- Biochemical Characterization and Tissue Distribution

Similar to PNPLA6, PNPLA7 shows lysophospholipase activity for LPC, producing fatty acids and GPC [31]. While PNPLA6 is predominantly expressed in the nervous system, PNPLA7 is mainly found in peripheral tissues such as the testes, skeletal muscle, heart, and adipose tissue.

- Structural Characteristics

PNPLA7 is a close homolog of PNPLA6 [31,89] and has a similar domain structure to PNPLA6, with an N-terminal transmembrane region and three nucleotide-binding motifs [31,89].

- Possible Functions

PNPLA7 is involved in choline metabolism by hydrolyzing LPC [31]. Interestingly, PNPLA7 is localized to the ER and tiny lipid droplets (LDs) in a catalytic domain-dependent manner [90]. PNPLA7-deficient mice were recently shown to have a premature aging phenotype and perish before adulthood due to metabolic defects, particularly in the liver (Makoto Murakami personal communication). However, the underlying molecular mechanisms remain unclear.

PNPLA8/ iPLA₂γ/group VIB PLA₂

- Historical Aspects

PNPLA8 is synonymous with a Ca²⁺-independent PLA₂γ (iPLA₂γ) and was originally cloned from human heart cDNA [91].

- Biochemical Characterization and Tissue Distribution

PNPLA8/iPLA₂γ exhibits a unique enzymatic activity [91]. It hydrolyzes a fatty acid at the *sn*-2 position (PLA₂ activity) when alkenyl PC is used as a substrate *in vitro*. It also hydrolyzes a fatty acid at the *sn*-1 position (PLA₁ activity) when diacyl PC with a polyunsaturated fatty acid at the *sn*-2 position is used as a substrate [32]. In humans, PNPLA8/iPLA₂γ mRNA expression is exceptionally high in the heart [91,92]. Immunohistochemical analysis in mouse myocardium demonstrated that PNPLA8/iPLA₂γ is associated with mitochondria and peroxisomes, reflecting dual protein localization motifs.

- Structural Characteristics

PNPLA8 is a close homolog of PNPLA9/iPLA₂β and has a similar active center but less homology at the N-terminus [93]. PNPLA9/iPLA₂β has four possible translation initiation sites, giving rise to proteins of 88, 77, 74, and 63 kDa. The N- and C-termini have mitochondrial and peroxisomal localization sequences, respectively, and the full-length 88- and 63 kDa translation products were observed to localize to mitochondria and peroxisomes, respectively, in the cell [94,95].

- Possible Functions

Liu et al. suggested that PNPLA8 is involved in cardiolipin remodeling and is essential for maintaining mitochondrial function [96]. A variety of phenotypes have been reported in PNPLA8-deficient mice [33], including failure to thrive, reduced resistance to exercise and myocardial stress, muscle weakness, decreased body temperature, adipose tissue atrophy, and neurodegeneration. Mutations in PNPLA8 in humans are associated with mitochondrial myopathy [97]. In a mouse model of myocardial ischemia, the levels of potential lipid mediators, including eicosanoids and lysophospholipids were altered in PNPLA8-deficient and PNPLA8-overexpressing mice, suggesting that PNPLA8 also has a function in the production of these lipid mediators [98]. In the liver, PNPLA8 is a candidate enzyme that supplies LPC, the substrate of PNPLA7.

5.2.2. cPLA₂ Family

The Group IV PLA₂ family is comprised of six intracellular enzymes commonly called cytosolic PLA₂α (cPLA₂α), cPLA₂β, cPLA₂γ, cPLA₂δ, cPLA₂ε, and cPLA₂ζ. Interestingly, they are mostly homologous to PLA and PLB/lysophospholipase of filamentous fungi, particularly in regions containing conserved residues involved in catalysis. Their primary functions appear to be exerted through their PLA₂ activity providing arachidonic acid for synthesis of eicosanoids. However, some members, *i.e.*, cPLA₂α/PLA₂G4A/GroupIVA PLA₂, cPLA₂β/PLA₂G4B/GroupIVB PLA₂, and cPLA₂ζ/PLA₂G4F/Group IVF PLA₂ also exhibit PLA₁ activity [35,34]. It should be noted that all these cPLA₂s have their own abilities to carry out multiple reactions to varying

degrees (PLA₂, PLA₁, lysophospholipase and transacylase activities). Thus, the conclusion that an enzyme has PLA₁ activity must be evaluated carefully, as an enzyme with both PLA₂ and lysophospholipase activity will apparently be judged to exhibit PLA₁ activity in an *in vitro* assay. The function of the PLA₁ activity of these enzymes remains completely unknown.

The X-ray crystal structures of cPLA₂ family members were determined only for cPLA₂α [99] (Figure 4). The structure explained the selectivity of the enzyme with arachidonic acid-containing GPLs using an unusual Ser-Asp dyad located in a deep cleft at the center of a predominantly hydrophobic funnel. AlphaFold predicted similar structures for cPLA₂β and cPLA₂ζ (Figure 4).

PLA2G16/group XVI PLA₂/PLAAT3/HRASLS3/H-Rev107

- Historical Aspects

PLAAT3 was found by subtraction cloning between sensitive and resistant fibroblasts to transformation by introducing H-Ras [100]. Overexpression of PLAAT3 in H-Ras-transformed fibroblasts suppressed cell proliferation and colony formation, indicating that PLAAT3 negatively regulates H-Ras' function [101].

- Biochemical Characterization and Tissue Distribution

PLAAT3 hydrolyses fatty acids at the *sn*-1 or *sn*-2 positions of PC and PE. Thus, it has both PLA₁ and PLA₂ activities, although the former is stronger than the latter. *In vitro*, PLAAT3 also shows weak N-acyltransferase and O-acyltransferase activities compared to other PLAAT family members [36,102]. PLAAT3 is highly expressed in adipocytes and is also known as adipose-specific PLA₂ (Ad-PLA₂) [103].

- Structural Characteristics

PLAAT3 has homology to lecithin-retinol acyltransferase (LRAT) and belongs to the NlpC/P60 superfamily. PLAAT3 contains a histidine-containing three-amino acid residue called the H-box and a cysteine-containing domain called the NC domain, which is thought to form the active site. In addition, it bears a proline-rich domain at the N-terminal side and a membrane-binding domain with a cluster of hydrophobic amino acids at the C-terminal side. These domains were reported to be essential for the regulation of H-Ras function [101]. A recent crystal structure analysis of PLAAT3 (Figure 4) revealed the catalytic mechanism of the enzyme [104].

- Possible Functions

PLAAT3-deficient mice are resistant to diet-induced obesity [105]. PLAAT3 is also involved in cancer invasion and metastasis [106] and is known to be involved in vitamin A metabolism [107], promotion of peroxisome formation, and production of ether GPLs [108]. Recently, Morishita et al. reported that PLAAT3 was involved in organelle degradation in the eye lens [109]. The eye lens of vertebrates is composed of fiber cells in which all membrane-bound organelles, including mitochondria, the endoplasmic reticulum, and lysosomes, undergo degradation during terminal differentiation to form an organelle-free zone. PLAAT3 in mammals and Plaaf1 (functional homolog) in zebrafish were shown to be essential in the organelle degradation in the eye lens.

Interestingly, these enzymes translocate from the cytosol to various organelles immediately before organelle degradation. The C-terminal transmembrane domain of the enzymes was shown to be essential to the process. It is speculated that for the complete digestion of GPLs, both PLA₁ and PLA₂ activities (PLB activity) of PLAAT3 are needed.

6. Conclusions and Perspectives

In this article, we summarize our current understanding of PLA₁ molecular structures and its activities. Genome projects have revealed a wide range of PLA₁-like molecules in the human genome, and subsequent biochemical studies have also revealed their nature. Of note, extracellular PLA₁ molecules such as mPA-PLA₁ α and PS-PLA₁ are now more clearly accepted as enzymes that produce lysophospholipid mediators such as LPA and LysoPS. Intracellular PLA₁s were also identified and an analysis of their mutants revealed that they exhibited essential physiological functions. However, the precise substrates and products and the physiological significance of the enzymatic reactions remain to be elucidated. Comprehensive lipidomics analysis of PLA₁ mutants and their overexpressing cells will help elucidate the true substrates, products, and functions of PLA₁ in future studies.

Author Contributions: J.A. wrote most of the manuscript. S.Y. and H.K. carried out a literature survey on the PLA₁ activity of various PLA₂ molecules. S.Y. created Table 1 and Figure 4, and H.K. created Figures 1, 2, and 3. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by AMED-LEAP (18gm0010004h0002; J.A.), KAKENHI (20K21379; J.A. and 20K15984; H.K.).

Acknowledgments: We are grateful to Makoto Murakami (The University of Tokyo) for sharing much information about the PLA₂ molecules and their PLA₁ activities.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

PLA₁; phospholipase A₁, PLA₂; phospholipase A₂, PLB; phospholipase B, GPL; glycerophospholipid, LPL; lysophospholipid, PC; phosphatidylcholine, PE; phosphatidylethanolamine, PS; phosphatidylserine, PI; phosphatidylinositol, PG; phosphatidylglycerol, PA; phosphatidic acid, LPC; lysophosphatidylcholine, LPA; lysophosphatidic acid, LysoPS; lysophosphatidylserine, TAG, triacylglycerol, DAG; diacylglycerol, MAG; monoacylglycerol, PS-PLA₁; PS-specific PLA₁, PA-PLA₁; PA-preferential PLA₁, mPA-PLA₁ α ; membrane-associated PA-selective PLA₁ α , mPA-PLA₁ β ; membrane-associated PA-selective PLA₁ β , PL; pancreatic lipase, LPL; lipoprotein lipase, HL; hepatic lipase, EL; endothelial lipase, ATX; autotaxin, iPLA₁; intracellular PLA₁, iPLA₂; intracellular PLA₂, sPLA₂; secretory PLA₂, cPLA₂; cytosolic PLA₂, PNPLA; patatin-like phospholipase, PLAAT; phospholipase A and acyltransferase.

References

1. Dennis, E.A. The growing phospholipase A₂ superfamily of signal transduction enzymes. *Trends Biochem. Sci.* **1997**, *22*, 1–2.
2. Murakami, M.; Nakatani, Y.; Atsumi, G.; Inoue, K.; Kudo, I. Regulatory functions of phospholipase A₂. *Crit. Rev. Immunol.* **1997**, *17*, 225–283.
3. Lykidis, A.; Jackowski, S. Regulation of mammalian cell membrane biosynthesis. *Prog. Nucleic Acid Res. Mol. Biol.* **2001**, *65*, 361–393.
4. Sonoda, H.; Aoki, J.; Hiramatsu, T.; Ishida, M.; Bandoh, K.; Nagai, Y.; Taguchi, R.; Inoue, K.; Arai, H. A novel phosphatidic acid-selective phospholipase A₁ that produces lysophosphatidic acid. *J. Biol. Chem.* **2002**, *277*, 34254–34263.
5. Bandoh, K.; Aoki, J.; Tsujimoto, M.; Arai, H.; Inoue, K. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. *FEBS Lett.* **2000**, *478*, 159–165.
6. Bandoh, K.; Aoki, J.; Hosono, H.; Kobayashi, S.; Kobayashi, T.; Murakami, M.K.; Tsujimoto, M.; Arai, H.; Inoue, K. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. *J. Biol. Chem.* **1999**, *274*, 27776–27785.
7. Robinson, M.; Waite, M. Physical-chemical requirements for the catalysis of substrates by lysosomal phospholipase A₁. *J. Biol. Chem.* **1983**, *258*, 14371–14378.
8. Kucera, G.L.; Miller, C.; Sisson, P.J.; Wilcox, R.W.; Wiemer, Z.; Waite, M. Hydrolysis of thioester analogs by rat liver phospholipase A₁. *J. Biol. Chem.* **1988**, *263*, 12964–12969.

9. Ueda, H.; Kobayashi, T.; Kishimoto, M.; Tsutsumi, T.; Okuyama, H. A possible pathway of phosphoinositide metabolism through EDTA-insensitive phospholipase A1 followed by lysophosphoinositide-specific phospholipase C in rat brain. *J. Neurochem.* **1993**, *61*, 1874–1881.
10. Ueda, H.; Kobayashi, T.; Kishimoto, M.; Tsutsumi, T.; Watanabe, S.; Okuyama, H. The presence of Ca(2+)-independent phospholipase A1 highly specific for phosphatidylinositol in bovine brain. *Biochem. Biophys. Res. Commun.* **1993**, *195*, 1272–1279.
11. Ueda, H.; Kobayashi, T.; Kishimoto, M.; Tsutsumi, T.; Okuyama, H. EDTA-insensitive deacylation of phosphatidylinositol in porcine platelet membranes. *Life Sci.* **1993**, *53*, 629–634.
12. Hostetler, K.Y.; Gardner, M.F.; Giordano, J.R. Purification of lysosomal phospholipase A and demonstration of proteins that inhibit phospholipase A in a lysosomal fraction from rat kidney cortex. *Biochemistry* **1986**, *25*, 6456–6461.
13. Waite, M. *The Phospholipases: Handbook of Lipid Research*; Plenum Publishing Corp: New York, NY, USA, 1987; pp. 79–110.
14. van den Bosch, H. *Phospholipases*; Elsevier: Amsterdam, The Netherlands, 1982; pp. 313–351.
15. Carriere, F.; Withers, M.C.T.H.; van Roussel, A.; Cambillau, C.; Verger, R. Structural basis for the substrate selectivity of pancreatic lipases and some related proteins. *Biochim. Biophys. Acta* **1998**, *1376*, 417–432.
16. Sato, T.; Aoki, J.; Nagai, Y.; Dohmae, N.; Takio, K.; Doi, T.; Arai, H.; Inoue, K. Serine phospholipid-specific phospholipase A that is secreted from activated platelets. A new member of the lipase family. *J. Biol. Chem.* **1997**, *272*, 2192–2198.
17. Nagai, Y.; Aoki, J.; Sato, T.; Amano, K.; Matsuda, Y.; Arai, H.; Inoue, K. An alternative splicing form of phosphatidylserine-specific phospholipase A1 that exhibits lysophosphatidylserine-specific lysophospholipase activity in humans. *J. Biol. Chem.* **1999**, *274*, 11053–11059.
18. Hiramatsu, T.; Sonoda, H.; Takanezawa, Y.; Morikawa, R.; Ishida, M.; Kasahara, K.; Sanai, Y.R.; Taguchi, J.; Aoki, H.A. Biochemical and molecular characterization of two phosphatidic acid-selective phospholipase A1s, mPA-PLA1alpha and mPA-PLA1beta. *J. Biol. Chem.* **2003**, *278*, 49438–49447.
19. Hide, W.A.; Chan, L.; Li, W.H. Structure and evolution of the lipase superfamily. *J. Lipid. Res.* **1992**, *33*, 167–178.
20. Winkler, F.K.; D'Arcy, A.; Hunziker, W. Structure of human pancreatic lipase. *Nature* **1990**, *343*, 771–774.
21. Carriere, F.; Thirstrup, K.; Hjorth, S.; Ferrato, F.; Nielsen, P.F.; Withers-Martinez, C.; Cambillau, C.; Boel, E.; Thim, L.; Verger, R. Pancreatic lipase structure-function relationships by domain exchange. *Biochemistry* **1997**, *36*, 239–248.
22. Higgs, H.N.; Glomset, J.A. Identification of a phosphatidic acid-preferring phospholipase A1 from bovine brain and testis. *Proc. Natl. Acad. Sci. USA* **1994**, *91*, 9574–9578.
23. Higgs, H.N.; Han, M.H.; Johnson, G.E.; Glomset, J.A. Cloning of a phosphatidic acid-preferring phospholipase A1 from bovine testis. *J. Biol. Chem.* **1998**, *273*, 5468–5477.
24. Nakajima, K.; Sonoda, H.; Mizoguchi, T.; Aoki, J.; Arai, H.; Nagahama, M.; Tagaya, M.; Tani, K. A novel phospholipase A1 with sequence homology to a mammalian Sec23p-interacting protein, p125. *J. Biol. Chem.* **2002**, *277*, 11329–11335.
25. Araki, M.; Ohshima, N.; Aso, C.; Konishi, A.; Obinata, H.; Tatei, K.; Izumi, T. Enzymatic characterization of recombinant rat DDHD2: a soluble diacylglycerol lipase. *J. Biochem.* **2016**, *160*, 269–279.
26. Inloes, J.M.; Hsu, K.L.; Dix, M.M.; Viader, A.; Masuda, K.; Takei, T.; Wood, M.R.; Cravatt, B.F. The hereditary spastic paraplegia-related enzyme DDHD2 is a principal brain triglyceride lipase. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 14924–14929.
27. Tani, K.; Mizoguchi, T.; Iwamatsu, A.; Hatsuzawa, K.; Tagaya, M. p125 is a novel mammalian Sec23p-interacting protein with structural similarity to phospholipid-modifying proteins. *J. Biol. Chem.* **1999**, *274*, 20505–20512.
28. Quistad, G.B.; Barlow, C.; Winrow, C.J.; Sparks, S.E.; Casida, J.E. Evidence that mouse brain neuropathy target esterase is a lysophospholipase. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 7983–7987.
29. Zaccheo, O.; Dinsdale, D.; Meacock, P.A.; Glynn, P. Neuropathy target esterase and its yeast homologue degrade phosphatidylcholine to glycerophosphocholine in living cells. *J. Biol. Chem.* **2004**, *279*, 24024–24033.
30. Muhlig-Versen, M.; da Cruz, A.B.; Tschape, J.A.; Moser, M.; Buttner, R.; Athenstaedt, K.; Glynn, P.; Kretzschmar, D. Loss of Swiss cheese/neuropathy target esterase activity causes disruption of phosphatidylcholine homeostasis and neuronal and glial death in adult *Drosophila*. *J. Neurosci.* **2005**, *25*, 2865–2873.
31. Kienesberger, P.C.; Lass, A.; Preiss-Landl, K.; Wolinski, H.; Kohlwein, S.D.; Zimmermann, R.; Zechner, R. Identification of an insulin-regulated lysophospholipase with homology to neuropathy target esterase. *J. Biol. Chem.* **2008**, *283*, 5908–5917.
32. Liu, X.; Moon, S.H.; Jenkins, C.M.; Sims, H.F.; Gross, R.W. Cyclooxygenase-2 Mediated Oxidation of 2-Arachidonoyl-Lysophospholipids Identifies Unknown Lipid Signaling Pathways. *Cell Chem. Biol.* **2016**, *23*, 1217–1227.
33. Mancuso, D.J.; Sims, H.F.; Han, X.; Jenkins, C.M.; Guan, S.P.; Yang, K.; Moon, S.H.; Pietka, T.; Abumrad, N.A.; Schlesinger, P.H.; et al. Genetic ablation of calcium-independent phospholipase A2gamma leads to alterations in mitochondrial lipid metabolism and function resulting in a deficient mitochondrial bioenergetic phenotype. *J. Biol. Chem.* **2007**, *282*, 34611–34622.
34. Pickard, R.T.; Striffler, B.A.; Kramer, R.M.; Sharp, J.D. Molecular cloning of two new human paralogs of 85-kDa cytosolic phospholipase A2. *J. Biol. Chem.* **1999**, *274*, 8823–8831.
35. Song, C.; Chang, X.J.; Bean, K.M.; Proia, M.S.; Knopf, J.L.; Kriz, R.W. Molecular characterization of cytosolic phospholipase A2-beta. *J. Biol. Chem.* **1999**, *274*, 17063–17067.
36. Uyama, T.; Morishita, J.; Jin, X.H.; Okamoto, Y.; Tsuboi, K.; Ueda, N. The tumor suppressor gene H-Rev107 functions as a novel Ca2+-independent cytosolic phospholipase A1/2 of the thiol hydrolase type. *J. Lipid. Res.* **2009**, *50*, 685–693.
37. Pete, M.J.; Ross, A.H.; Exton, J.H. Purification and properties of phospholipase A1 from bovine brain. *J. Biol. Chem.* **1994**, *269*, 19494–19500.

38. Uchiyama, S.; Miyazaki, Y.; Amakasu, Y.; Kuwata, H.; Nakatani, Y.; Atsumi, G.; Murakami, M.; Kudo, I. Characterization of heparin low-affinity phospholipase A1 present in brain and testicular tissue. *J. Biochem.* **1999**, *125*, 1001–1010.
39. Horigome, K.; Hayakawa, M.; Inoue, K.; Nojima, S. Selective release of phospholipase A2 and lysophosphatidylserine-specific lysophospholipase from rat platelets. *J. Biochem.* **1987**, *101*, 53–61.
40. Horigome, K.; Hayakawa, M.; Inoue, K.; Nojima, S. Purification and characterization of phospholipase A2 released from rat platelets. *J. Biochem.* **1987**, *101*, 625–631.
41. Jumper, J.; Evans, R.; Pritzel, A.; Green, T.; Figurnov, M.; Ronneberger, O.; Tunyasuvunakool, K.; Bates, R.; Žídek, A.; Potapenko, A.; et al. Highly accurate protein structure prediction with AlphaFold. *Nature* **2021**, *596*, 583–589.
42. Higashi, S.; Kobayashi, T.; Kudo, I.; Inoue, K. Purification and characterization of lysophospholipase released from rat platelets. *J. Biochem.* **1988**, *103*, 442–447.
43. Aoki, J.; Nagai, Y.; Hosono, H.; Inoue, K.; Arai, H. Structure and function of phosphatidylserine-specific phospholipase A1. *Biochim. Biophys. Acta* **2002**, *1582*, 26–32.
44. Nakamura, K.; Igarashi, K.; Ohkawa, R.; Saiki, N.; Nagasaki, M.; Uno, K.; Hayashi, N.; Sawada, T.; Syukuya, K.; Yokota, H.; et al. A novel enzyme immunoassay for the determination of phosphatidylserine-specific phospholipase A(1) in human serum samples. *Clin Chim Acta* **2010**, *411*, 1090–1094.
45. Sawada, T.; Kurano, M.; Shirai, H.; Iwasaki, Y.; Tahara, K.; Hayashi, H.; Igarashi, K.; Fujio, K.; Aoki, J.; Yatomi, Y. Serum phosphatidylserine-specific phospholipase A 1 as a novel biomarker for monitoring systemic lupus erythematosus disease activity. *Int. J. Rheum. Dis.* **2019**, *22*, 2059–2066.
46. Yokoyama, K.; Kudo, I.; Inoue, K. Phospholipid degradation in rat calcium ionophore-activated platelets is catalyzed mainly by two discrete secretory phospholipase As. *J. Biochem.* **1995**, *117*, 1280–1287.
47. Martin, T.W.; Lagunoff, D. Interactions of lysophospholipids and mast cells. *Nature* **1979**, *279*, 250–252.
48. Tamori, N.Y.; Horigome, K.; Inoue, K.; Nojima, S. Metabolism of lysophosphatidylserine, a potentiator of histamine release in rat mast cells. *J. Biochem.* **1986**, *100*, 581–590.
49. Horigome, K.; Tamori, N.Y.; Inoue, K.; Nojima, S. Effect of serine phospholipid structure on the enhancement of concanavalin A-induced degranulation in rat mast cells. *J. Biochem.* **1986**, *100*, 571–579.
50. Bruni, A.; Monastra, G.; Bellini, F.; Toffano, G. Autacoid properties of lysophosphatidylserine. *Prog. Clin. Biol. Res.* **1988**, *282*, 165–179.
51. Hosono, H.; Aoki, J.; Nagai, Y.; Bandoh, K.; Ishida, M.; Taguchi, R.; Arai, H.; Inoue, K. Phosphatidylserine-specific phospholipase A1 stimulates histamine release from rat peritoneal mast cells through production of 2-acyl-1-lysophosphatidylserine. *J. Biol. Chem.* **2001**, *276*, 29664–29670.
52. Hecht, J.H.; Weiner, J.A.; Post, S.R.; Chun, J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. *J. Cell Biol.* **1996**, *135*, 1071–1083.
53. An, S.; Bleu, T.; Hallmark, O.G.; Goetzl, E.J. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. *J. Biol. Chem.* **1998**, *273*, 7906–7910.
54. Hayashi, K.; Takahashi, M.; Nishida, W.; Yoshida, K.; Ohkawa, Y.; Kitabatake, A.; Aoki, J.; Arai, H.; Sobue, K. Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. *Circ. Res.* **2001**, *89*, 251–258.
55. Tokumura, A.; Iimori, M.; Nishioka, Y.; Kitahara, M.; Sakashita, M.; Tanaka, S. Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta. *Am. J. Physiol.* **1994**, *267*, C204–C210.
56. Kurano, M.; Suzuki, A.; Inoue, A.; Tokuhara, Y.; Kano, K.; Matsumoto, H.; Igarashi, K.; Ohkawa, R.; Nakamura, K.; Dohi, T.; et al. Possible involvement of minor lysophospholipids in the increase in plasma lysophosphatidic acid in acute coronary syndrome. *Arterioscler. Thromb. Vasc. Biol.* **2015**, *35*, 463–470.
57. Aoki, J.; Inoue, A.; Okudaira, S. Two pathways for lysophosphatidic acid production. *Biochim. Biophys. Acta* **2008**, *1781*, 513–518.
58. Inoue, A.; Arima, N.; Ishiguro, J.; Prestwich, G.D.; Arai, H.; Aoki, J. LPA-producing enzyme PA-PLA₁α regulates hair follicle development by modulating EGFR signalling. *EMBO J.* **2011**, *30*, 4248–4260.
59. Foell, J.L.; Hesse, M.; Volkmer, I.; Schmiedel, B.J.; Neumann, I.; Staeger, M.S. Membrane-associated phospholipase A1 beta (LIPI) Is an Ewing tumour-associated cancer/testis antigen. *Pediatr. Blood Cancer* **2008**, *51*, 228–234.
60. Kazantseva, A.; Goltsov, A.; Zinchenko, R.; Grigorenko, A.P.; Abrukova, A.V.; Moliaka, Y.K.; Kirillov, A.G.; Guo, Z.; Lyle, S.; Ginter, E.K.; et al. Human hair growth deficiency is linked to a genetic defect in the phospholipase gene LIPH. *Science* **2006**, *314*, 982–985.
61. Shimomura, Y.; Wajid, M.; Ishii, Y.; Shapiro, L.; Petukhova, L.; Gordon, D.; Christiano, A.M. Disruption of P2RY5, an orphan G protein-coupled receptor, underlies autosomal recessive woolly hair. *Nat. Genet.* **2008**, *40*, 335–339.
62. Pasternack, S.M.; von Kügelgen, I.; al Aboud, K.; Lee, T.A.; Rüschenhoff, F.; Voss, K.; Hillmer, A.M.; Molderings, G.J.; Franz, T.; Ramirez, A.; et al. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. *Nat. Genet.* **2008**, *40*, 329–334.
63. Yanagida, K.; Masago, K.; Nakanishi, H.; Kihara, Y.; Hamano, F.; Tajima, Y.; Taguchi, R.; Shimizu, T.; Ishii, S. Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. *J. Biol. Chem.* **2009**, *284*, 17731–17741.
64. Soldatova, L.; Kochoumian, L.; King, T.P. Sequence similarity of a hornet (*D. maculata*) venom allergen phospholipase A1 with mammalian lipases. *FEBS Lett.* **1993**, *320*, 145–149.
65. Shamburek, R.D.; Zech, L.A.; Cooper, P.S.; Vandebroek, J.M.; Schwartz, C.C. Disappearance of two major phosphatidylcholines from plasma is predominantly via LCAT and hepatic lipase. *Am. J. Physiol.* **1996**, *271*, E1073–E1082.

66. MMcCoy, G.; Sun, G.S.; Marchadier, D.; Maugeais, C.; Glick, J.M.; Rader, D.J. Characterization of the lipolytic activity of endothelial lipase. *J. Lipid. Res.* **2002**, *43*, 921–929.
67. Higgs, H.N.; Glomset, J.A. Purification and properties of a phosphatidic acid-preferring phospholipase A1 from bovine testis. Examination of the molecular basis of its activation. *J. Biol. Chem.* **1996**, *271*, 10874–10883.
68. Barlowe, C.; Schekman, R. SEC12 encodes a guanine-nucleotide-exchange factor essential for transport vesicle budding from the ER. *Nature* **1993**, *365*, 347–349.
69. Han, M.H.; Han, D.K.; Aebersold, R.H.; Glomset, J.A. Effects of protein kinase CK2, extracellular signal-regulated kinase 2, and protein phosphatase 2A on a phosphatidic acid-preferring phospholipase A1. *J. Biol. Chem.* **2001**, *276*, 27698–27708.
70. Matsumoto, N.; Nemoto-Sasaki, Y.; Oka, S.; Arai, S.; Wada, I.; Yamashita, A. Phosphorylation of human phospholipase A1 DDHD1 at newly identified phosphosites affects its subcellular localization. *J. Biol. Chem.* **2021**, *297*, 100851.
71. Miyazawa, D.; Ikemoto, A.; Fujii, Y.; Okuyama, H. Partial purification and characterization of phosphatidic acid-specific phospholipase A(1) in porcine platelet membranes. *Biochim. Biophys. Acta* **2003**, *1631*, 17–25.
72. Pete, M.J.; Exton, J.H. Phospholipid interactions affect substrate hydrolysis by bovine brain phospholipase A1. *Biochim. Biophys. Acta* **1995**, *1256*, 367–373.
73. Giudice, T.L.; Lombardi, F.; Santorelli, F.M.; Kawarai, T.; Orlandi, A. Hereditary spastic paraplegia: clinical-genetic characteristics and evolving molecular mechanisms. *Exp. Neurol.* **2014**, *261*, 518–539.
74. Tesson, C.; Nawara, M.; Salih, M.A.; Rossignol, R.; Zaki, M.S.; al Balwi, M.; Schule, R.; Mignot, C.; Obre, E.; Bouhouche, A.; et al. Alteration of fatty-acid-metabolizing enzymes affects mitochondrial form and function in hereditary spastic paraplegia. *Am. J. Hum. Genet.* **2012**, *91*, 1051–1064.
75. Yamashita, A.; Kumazawa, T.; Koga, H.; Suzuki, N.; Oka, S.; Sugiura, T. Generation of lysophosphatidylinositol by DDHD domain containing 1 (DDHD1): Possible involvement of phospholipase D/phosphatidic acid in the activation of DDHD1. *Biochim. Biophys. Acta* **2010**, *1801*, 711–720.
76. Inloes, J.M.; Jing, H.; Cravatt, B.F. The Spastic Paraplegia-Associated Phospholipase DDHD1 Is a Primary Brain Phosphatidylinositol Lipase. *Biochemistry* **2018**, *57*, 5759–5767.
77. Baba, T.; Kashiwagi, Y.; Arimitsu, N.; Kogure, T.; Edo, A.; Maruyama, T.; Nakao, K.; Nakanishi, H.; Kinoshita, M.; Frohman, M.A.; et al. Phosphatidic acid (PA)-preferring phospholipase A1 regulates mitochondrial dynamics. *J. Biol. Chem.* **2014**, *289*, 11497–11511.
78. Morikawa, R.K.; Aoki, J.; Kano, F.; Murata, M.; Yamamoto, A.; Tsujimoto, M.; Arai, H. Intracellular phospholipase A1gamma (iPLA1gamma) is a novel factor involved in coat protein complex I- and Rab6-independent retrograde transport between the endoplasmic reticulum and the Golgi complex. *J. Biol. Chem.* **2009**, *284*, 26620–26630.
79. Gonzalez, M.; Nampoothiri, S.; Kornblum, C.; Oteyza, A.C.; Walter, J.; Konidari, I.; Hulme, W.; Speziani, F.; Schöls, L.; Züchner, S.; et al. Mutations in phospholipase DDHD2 cause autosomal recessive hereditary spastic paraplegia (SPG54). *Eur. J. Hum. Genet.* **2013**, *21*, 1214–1218.
80. Maruyama, T.; Baba, T.; Maemoto, Y.; Hara-Miyauchi, C.; Hasegawa-Ogawa, M.; Enda, Y.O.; Matsumoto, K.; Arimitsu, N.; Nakao, K.; Hamamoto, H.; et al. Loss of DDHD2, whose mutation causes spastic paraplegia, promotes reactive oxygen species generation and apoptosis. *Cell Death Dis.* **2018**, *9*, 797.
81. Kienesberger, P.C.; Oberer, M.; Lass, A.; Zechner, R. Mammalian patatin domain containing proteins: a family with diverse lipolytic activities involved in multiple biological functions. *J. Lipid. Res.* **2009**, *50*, S63–S68.
82. Winrow, C.J.; Hemming, M.L.; Allen, D.M.; Quistad, G.B.; Casida, J.E.; Barlow, C. Loss of neuropathy target esterase in mice links organophosphate exposure to hyperactivity. *Nat. Genet.* **2003**, *33*, 477–485.
83. Moser, M.; Li, Y.; Vaupel, K.; Kretzschmar, D.; Kluge, R.; Glynn, P.; Buettner, R. Placental failure and impaired vasculogenesis result in embryonic lethality for neuropathy target esterase-deficient mice. *Mol. Cell. Biol.* **2004**, *24*, 1667–1679.
84. Akassoglou, K.; Malester, B.; Xu, J.; Tessarollo, L.; Rosenbluth, J.; Chao, M.V. Brain-specific deletion of neuropathy target esterase/swisscheese results in neurodegeneration. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 5075–5080.
85. Rainier, S.; Bui, M.; Mark, E.; Thomas, D.; Tokarz, D.; Ming, L.; Delaney, C.E.; Richardson, R.J.; Albers, J.W.; Matsunami, N.; et al. Neuropathy target esterase gene mutations cause motor neuron disease. *Am. J. Hum. Genet.* **2008**, *82*, 780–785.
86. Synofzik, M.; Gonzalez, M.A.; Lourenco, C.M.; Coutelier, M.; Haack, T.B.; Rebelo, A.; Hannequin, D.; Strom, T.M.; Prokisch, H.; Kernstock, C.; et al. PNPLA6 mutations cause Boucher-Neuhauser and Gordon Holmes syndromes as part of a broad neurodegenerative spectrum. *Brain* **2014**, *137*, 69–77.
87. Kmoch, S.; Majewski, J.; Ramamurthy, V.; Cao, S.; Fahiminiya, S.; Ren, H.; MacDonald, I.M.; Lopez, I.; Sun, V.; Keser, V.; et al. Mutations in PNPLA6 are linked to photoreceptor degeneration and various forms of childhood blindness. *Nat. Commun.* **2015**, *6*, 5614.
88. Gallazzini, M.; Ferraris, J.D.; Kunin, M.; Morris, R.G.; Burg, M.B. Neuropathy target esterase catalyzes osmoprotective renal synthesis of glycerophosphocholine in response to high NaCl. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 15260–15265.
89. Richardson, R.J.; Hein, N.D.; Wijeyesakere, S.J.; Fink, J.K.; Makhaeva, G.F. Neuropathy target esterase (NTE): overview and future. *Chem. Biol. Interact.* **2013**, *203*, 238–244.
90. Heier, C.; Huang, B.K.F.; Eichmann, T.O.; Xie, H.; Zechner, R.; Chang, P. The phospholipase PNPLA7 functions as a lysophosphatidylcholine hydrolase and interacts with lipid droplets through its catalytic domain. *J. Biol. Chem.* **2017**, *292*, 19087–19098.

91. Moon, S.H.; Jenkins, C.M.; Liu, X.; Guan, S.; Mancuso, D.J.; Gross, R.W. Activation of mitochondrial calcium-independent phospholipase A2 γ (iPLA2 γ) by divalent cations mediating arachidonate release and production of downstream eicosanoids. *J. Biol. Chem.* **2012**, *287*, 14880–14895.
92. Hazen, S.L.; Stuppy, R.J.; Gross, R.W. Purification and characterization of canine myocardial cytosolic phospholipase A2. A calcium-independent phospholipase with absolute f1-2 regiospecificity for diradyl glycerophospholipids. *J. Biol. Chem.* **1990**, *265*, 10622–10630.
93. Jabůrek, M.; Průchová, P.; Holendová, B.; Galkin, A.; Ježek, P. Antioxidant Synergy of Mitochondrial Phospholipase PNPLA8/iPLA2 γ with Fatty Acid-Conducting SLC25 Gene Family Transporters. *Antioxidants* **2021**, *10*, 678.
94. Mancuso, D.J.; Jenkins, C.M.; Sims, H.F.; Cohen, J.M.; Yang, J.; Gross, R.W. Complex transcriptional and translational regulation of iPLA γ resulting in multiple gene products containing dual competing sites for mitochondrial or peroxisomal localization. *Eur. J. Biochem.* **2004**, *271*, 4709–4724.
95. Murakami, M.; Masuda, S.; Ueda-Semmyo, K.; Yoda, E.; Kuwata, H.; Takanezawa, Y.; Aoki, J.; Arai, H.; Sumimoto, H.; Ishikawa, Y.; et al. Group VIB Ca²⁺-independent phospholipase A2 γ promotes cellular membrane hydrolysis and prostaglandin production in a manner distinct from other intracellular phospholipases A2. *J. Biol. Chem.* **2005**, *280*, 14028–14041.
96. Liu, G.Y.; Moon, S.H.; Jenkins, C.M.; Li, M.; Sims, H.F.; Guan, S.; Gross, R.W. The phospholipase iPLA 2 γ is a major mediator releasing oxidized aliphatic chains from cardiolipin, integrating mitochondrial bioenergetics and signaling. *J. Biol. Chem.* **2017**, *292*, 10672–10684.
97. Saunders, C.J.; Moon, S.H.; Liu, X.; Thiffault, I.; Coffman, K.; LePichon, J.B.; Taboada, E.; Smith, L.D.; Farrow, E.G.; Miller, N.; et al. Loss of function variants in human PNPLA8 encoding calcium-independent phospholipase A2 γ recapitulate the mitochondriopathy of the homologous null mouse. *Hum. Mutat.* **2015**, *36*, 301–306.
98. Moon, S.H.; Mancuso, D.J.; Sims, H.F.; Liu, X.; Nguyen, A.L.; Yang, K.; Guan, S.; Dilthey, B.G.; Jenkins, C.M.; Weinheimer, C.J.; et al. Cardiac Myocyte-specific Knock-out of Calcium-independent Phospholipase A2 γ (iPLA2 γ) Decreases Oxidized Fatty Acids during Ischemia/Reperfusion and Reduces Infarct Size. *J. Biol. Chem.* **2016**, *291*, 19687–19700.
99. Dessen, A.; Tang, J.; Schmidt, H.; Stahl, M.; Clark, J.D.; Sehra, J.; Somers, W.S. Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism. *Cell* **1999**, *97*, 349–360.
100. Hajnal, A.; Klemenz, R.; Schäfer, R. Subtraction cloning of H-rev107, a gene specifically expressed in H-ras resistant fibroblasts. *Oncogene* **1994**, *9*, 479–490.
101. Sers, C.; Emmenegger, U.; Husmann, K.; Bucher, K.; Andres, A.C.; Schäfer, R. Growth-inhibitory activity and downregulation of the class II tumor-suppressor gene H-rev107 in tumor cell lines and experimental tumors. *J. Cell. Biol.* **1997**, *136*, 935–944.
102. Shinohara, N.; Uyama, T.; Jin, X.H.; Tsuboi, K.; Tonai, T.; Houchi, H.; Ueda, N. Enzymological analysis of the tumor suppressor A-C1 reveals a novel group of phospholipid-metabolizing enzymes. *J. Lipid. Res.* **2011**, *52*, 1927–1935.
103. Duncan, E.; Sarkadi-Nagy, E.; Jaworski, K.; Ahmadian, M.; Sul, H.S. Identification and functional characterization of adipose-specific phospholipase A2 (AdPLA). *J. Biol. Chem.* **2008**, *283*, 25428–25436.
104. Golczak, M.; Kiser, P.D.; Sears, A.E.; Lodowski, D.T.; Blaner, W.S.; Palczewski, K. Structural basis for the acyltransferase activity of lecithin:retinol acyltransferase-like proteins. *J. Biol. Chem.* **2012**, *287*, 23790–23807.
105. Jaworski, K.; Ahmadian, M.; Duncan, R.E.; Sarkadi-Nagy, E.; Varady, K.A.; Hellerstein, M.K.; Lee, H.Y.; Samuel, V.T.; Shulman, G.I.; Kim, K.H.; et al. AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency. *Nat. Med.* **2009**, *15*, 159–168.
106. Xiong, S.; Tu, H.; Kollareddy, M.; Pant, V.; Li, Q.; Zhang, Y.; Jackson, J.G.; Suh, Y.A.; Elizondo-Fraire, A.C.; Yang, P.; et al. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 11145–11150.
107. Golczak, M.; Sears, A.E.; Kiser, P.D.; Palczewski, K. LRAT-specific domain facilitates vitamin A metabolism by domain swapping in HRASLS3. *Nat. Chem. Biol.* **2015**, *11*, 26–32.
108. Uyama, T.; Kawai, K.; Kono, N.; Watanabe, M.; Tsuboi, K.; Inoue, T.; Araki, N.; Arai, H.; Ueda, N. Interaction of Phospholipase A/Acyltransferase-3 with Pex19p: A POSSIBLE INVOLVEMENT IN THE DOWN-REGULATION OF PEROXISOMES. *J. Biol. Chem.* **2015**, *290*, 17520–17534.
109. Morishita, H.; Eguchi, T.; Tsukamoto, S.; Sakamaki, Y.; Takahashi, S.; Saito, C.; Koyama-Honda, I.; Mizushima, N. Organelle degradation in the lens by PLAAT phospholipases. *Nature* **2021**, *592*, 634–638.